Menu
Edvard Smith
Sweden
Department of Laboratory Medicine
Karolinska Institute
Fellow:
Involved in these STIAS projects
Involved in these STIAS projects
The beauty of BTK inhibitors is that they impair tumor development by blocking normal, unmutated BTK, causing many lymphoid tumors to be sensitive, as we have reviewed. Thus, for each tumor type a majority...
BTK is a cytoplasmic protein-tyrosine kinase, whose corresponding gene was isolated in the early 1990s. BTK was initially identified by positional cloning of the gene causing X-linked agammaglobulinemia...
Related news
Related news
Related publications
Related publications
Journal Article
Smith, C. I. Edvard, Peter Bergman and Daniel W. Hagey. 2022. Estimating the number of diseases – the concept of rare, ultra-rare, and hyper-rare. iScience, 25(8), 104698. https://doi.org/10.1016/j.isci.2022.104698
Journal Article
Smith, C.I. Edvard and Rula Zain. 2019. Therapeutic Oligonucleotides: State of the Art. Annual Review of Pharmacology and Toxicology, 59(1), 605–630. https://doi.org/10.1146/annurev-pharmtox-010818-021050
Share Edvard Smith's STIAS profile:
Share on whatsapp
WhatsApp
Share on email
Email
Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn
Is any information on this page incorrect or outdated? Please notify Ms. Nel-Mari Loock at [email protected].